About Us

Dr. Paulson is a world renowned glycobiologist and an
expert on influenza viral receptor biology. He is a
Professor of Molecular Biology at The Scripps Research
Institute. Dr. Paulson served as the President of The
Society for Glycobiology. He is a member of the editorial
board for the Journal of Biological Chemistry and
Glycobiology, a Honorary Member of the American Society
of Clinical Investigation. He is currently the Principal
Investigator on a $34 million NIGMS grant to fund, the

Dr. Levine has over 25 years of experience in process
development, manufacturing and operations in the
biopharmaceutical industry. He is the Founder and
President of BioProcess Technology Consultants, Inc., a
leading biopharmaceutical CMC consulting firm which
provides assistance with all aspects of process
development, manufacturing, quality control, quality
assurance, and validation of biopharmaceutical
manufacturing processes and facilities. Dr. Levine is

Dr. Cavagnaro is an expert toxicologist, and founder &
president of Access BIO L.C., a consultancy specializing in
regulatory strategies and product development. She has
over 25 years of industry and government experience
including over 8 years with the FDA. During her tenure at
FDA she served as the Director of Quality Assurance for
CBER, was appointed to the SBRS, served as FDA’s topic
lead for safety for the ICH initiative for 7 years and
rapporteur for the ICH S6 Preclinical Safety Evaluation of

Dr. Hayden is an internationally recognized expert on
respiratory viral infections and a leading clinical
investigator on influenza antiviral agents. He is currently
an advisor to WHO for its global effort to fight influenza
pandemics. He is a Stuart S. Richardson Professor of
Clinical Virology and Professor of Internal Medicine at
the University of Virginia School of Medicine. He has
served as the editor for Antimicrobial Agents and

Consortium for Functional Glycomics. Since 1990, he served as the Vice
President of Research, Chief Scientific Officer and Board Member of Cytel
Corporation until its merger with Epimmune in 1999. Previously, Dr. Paulson
was a Professor and Vice-Chair of the Department of Biological Chemistry of
the University of California, Los Angeles, School of Medicine. Dr. Paulson
holds a Ph.D. degree in Biochemistry from the University of Illinois at
Champaign-Urbana.

currently a member of the Editorial Advisory Boards of International BioPharm
Magazine, BioProcess International, and Bio/Pharmaceutical Outsourcing
Report, and is also co-editor of a directory of biologics contract manufacturers.
He is a member of the Scientific Advisory Board of Acretia, Inc., and serves as
acting Chief Technology Officer for Triton BioSystems, Inc. Prior to founding
BioProcess Technology Consultants, Dr. Levine was Vice President of
Manufacturing Operations at Repligen Corporation for all process
development and manufacturing activities. He previously held positions of
increasing responsibility in process development and manufacturing at
Genentech, Amgen, and Xoma. Dr. Levine holds a Ph.D. degree in
Biochemistry from the University of Chicago.

Chemotherapy. He has also served on editorial boards for Antiviral
Research, Antiviral Therapy, and the Journal of Antimicrobial
Chemotherapy. Dr. Hayden is a member of the Executive Committee for the
NIAID - University of Alabama Collaborative Antiviral Study Group and the
Board of Directors for the International Society for Antiviral Research. Dr.
Hayden focuses his research activities on the pathogenesis of respiratory
viral infections and the application of antiviral agents for their prevention and
treatment. The scope of his studies has ranged from antiviral mechanisms
of action to clinical trials involving experimentally induced and naturally
occurring infections. Dr. Hayden holds a M.D. degree from Stanford
University and is board-certified in internal medicine and infectious
diseases.

Biotechnology Products. She also chaired the working group responsible
for the 1996 FDA Guidance Concerning Demonstration of Comparability of
Human Biological Products including Therapeutic Biotechnology-derived
Products. Prior to joining the FDA, Dr. Cavagnaro was a principal study
director for biotechnology products at Covance. Dr. Cavanaro is the past
chair of the Regulatory Affairs Professional Society, and currently serves as
chair of BioSafe a Biotechnology Industry Organization (BIO), which identifies
key regulatory issues related to the preclinical safety evaluation of
biopharmaceutical products. Dr. Cavagnaro holds a PhD degree in
Biochemistry form the University of North Carolina, Chapel Hill.

Dr. Webster is Professor at St. Jude Children’s Research
Hospital and holds the Rose Marie Thomas Chair. Since
1975, he has been Director of the World Health
Organization (WHO) Collaborating Center for Studies on
interests include the emergence and control of influenza
viruses, viral immunology, the structure and function of
influenza virus proteins and the development of new
vaccines and antivirals. The major focus of his research is
the importance of influenza viruses in wild aquatic birds

as a major reservoir of influenza viruses and their role in the evolution of new
pandemic strains for humans and lower animals. His curriculum vitae contain
over 500 original articles and reviews on influenza viruses. He has trained
many scientists who now reviews on influenza viruses. He has trained many
scientists who now contribute to our understanding of the evolution and
pathogenesis of influenza. Dr. Webster is a member of National Academy of
Sciences and a Fellow of the Royal Society, London. He earned his Ph.D.
from the Australian National University.National University.